Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BI 1595043 With and Without Food
NCT04789291Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BI 1595043 in Crohn's disease and inflammatory bowel disease (IBD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve in Plasma (0 to last quantifiable point) at 168 hours and Maximum Measured Concentration in Plasma at 168 hours. Started May 2021; status: completed.
02
Drugs
BI 1595043
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT04789291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04789291.